多潘立酮能否缩短小儿视频胶囊内镜检查的通过时间？一项随机对照试验。
Can domperidone decrease transit time of pediatric video capsule endoscopy? A randomized controlled trial.
作者信息
Wu Jie, Ye Ziqing, Xue Aijuan, Huang Ying
机构信息
Department of Gastroenterology, Children's Hospital of Fudan University, Shanghai, China.
出版信息
Transl Pediatr. 2021 Feb;10(2):344-349. doi: 10.21037/tp-20-273.
BACKGROUND
The complete examination rate of video capsule endoscopy can be increased by reduced gastric transit time (GTT) and or small bowel transit time (SBTT). This study aims to examine whether the prokinetic domperidone reduces GTT and/or SBTT in pediatric patients undergoing video capsule endoscopy (VCE).
METHODS
We performed a single-center randomized controlled trial (n=200) to evaluate the effect of domperidone on GTT and SBTT among pediatric patients in a tertiary university-affiliated hospital for children. We explored whether patients randomized to domperidone had increased GTT, SBTT (primary outcomes) or higher complete examination rate (secondary outcome). The safety outcomes were the adverse effects in the domperidone group. This study was registered on ClinicalTrials.gov (NCT03662113).
RESULTS
Demographic features including gender and age were similar between the 100 patients of the domperidone group and the 100 patients of the control group. The median GTT was 67.5 minutes (44.8-117.5) in the domperidone group and 80.0 minutes (42.0-128.0) in the control group, while the median SBTT was 317 minutes (231-436) and 323 minutes (225-426), respectively. There were no significant differences in GTT (P=0.49) and SBTT (P=0.52) between the two groups. The complete examination rate was 97% and 98% in the domperidone and control groups, respectively (P=1.00).
CONCLUSIONS
Domperidone shows no effect on GTT, SBTT and complete examination rate in pediatric patients receiving VCE.
背景
缩短胃排空时间（GTT）和/或小肠转运时间（SBTT）可提高视频胶囊内镜的完整检查率。本研究旨在探讨促动力药多潘立酮是否能缩短接受视频胶囊内镜检查（VCE）的儿科患者的GTT和/或SBTT。
方法
我们在一家三级大学附属医院进行了一项单中心随机对照试验（n = 200），以评估多潘立酮对儿科患者GTT和SBTT的影响。我们探究了随机分配接受多潘立酮治疗的患者的GTT、SBTT（主要结局）是否增加或完整检查率是否更高（次要结局）。安全性结局为多潘立酮组的不良反应。本研究已在ClinicalTrials.gov注册（NCT03662113）。
结果
多潘立酮组的100例患者与对照组的100例患者在性别和年龄等人口统计学特征方面相似。多潘立酮组的GTT中位数为67.5分钟（44.8 - 117.5），对照组为80.0分钟（42.0 - 128.0），而SBTT中位数分别为317分钟（231 - 436）和323分钟（225 - 426）。两组之间的GTT（P = 0.49）和SBTT（P = 0.52）无显著差异。多潘立酮组和对照组的完整检查率分别为97%和98%（P = 1.00）。
结论
多潘立酮对接受VCE的儿科患者的GTT、SBTT和完整检查率无影响。
Zotero 插件